Severity
Low
FDA Drug recall · Reported February 7, 2018
Subpotent Drug: The product is sub-potent prior to its 90-day beyond use date.
Jcb Laboratories LLC recalled Cefuroxime, Ophthalmic Solution for Injection, 10 mg/mL, 0.3 mL single-use syringe. This… - a low-severity action.
Cefuroxime, Ophthalmic Solution for Injection, 10 mg/mL, 0.3 mL single-use syringe. This… was recalled by Jcb Laboratories LLC in February 7, 2018. Reason: Subpotent Drug: The product is sub-potent prior to its 90-day beyond use date.. Check the official notice for the remedy. Verify recall #D-0246-2018 with the FDA Drug before acting.
The recall
Jcb Laboratories LLC issued this low-severity FDA Drug recall-Subpotent Drug: The product is sub-potent prior to its 90-day beyond use date..
Sourced from official FDA Drug enforcement records. Verify recall #D-0246-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0246-2018) was formally reported on February 7, 2018, with the manufacturer initiating the action on January 24, 2018. It is classified under Low severity (Class III), with a current status of Terminated. Jcb Laboratories LLC is listed as the recalling firm, operating out of Wichita, KS. Federal records list the affected scope as 6,510 syriges.
The documented reason for this recall is: Subpotent Drug: The product is sub-potent prior to its 90-day beyond use date. Distribution data in the federal record shows the product reached: Nationwide within USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,436 drugs & medications recalls on record
Of 88,001 recalls with an agency hazard classification, 19,020 are high severity, 64,468 moderate, and 4,513 low. A further 16,157 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified low severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Low
Affected scope
6,510 syriges
Related Recalls
6
6 from same agency
Cefuroxime, Ophthalmic Solution for Injection, 10 mg/mL, 0.3 mL single-use syringe. This is a Compounded Drug, Hospital & Office Use Only, Not for Resale. Fagron Sterile Services/JCB Laboratories, 7335 W. 33rd St. N., Wichita, KS 67205
Subpotent Drug: The product is sub-potent prior to its 90-day beyond use date.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Low (Class III) |
| Status | Terminated |
| Recall number | D-0246-2018 |
| Date reported | February 7, 2018 |
| Date initiated | January 24, 2018 |
| Recalling firm | Jcb Laboratories LLC |
| Firm location | Wichita, KS |
| Affected scope | 6,510 syriges |
| Distribution | Nationwide within USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Two federal-filing-derived peer sets for this notice, both outside the same recalling firm and filing state so the neighborhoods are not firm or geographic containment.
Same archive severity grade (Low), closest by report date among other firms and states.
Same product category, closest by report date among other firms and states (deduped against the severity set).
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Showing 5 of 14436 other recalls in this category.
Rohto-Mentholatum (Vietnam) Co., Ltd. · 2026-07-29
Major Pharmaceuticals · 2026-07-29
Rohto-Mentholatum (Vietnam) Co., Ltd. · 2026-07-29
Major Pharmaceuticals · 2026-07-29
Major Pharmaceuticals · 2026-07-29
Compare this recall with Rohto Cooling Eye Drops Max Strength (naphazoline hydrochlo… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 7, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.